Login
Navigate Fool.com
Will PTCT beat
the market?

PTC Therapeutics, Inc. (NASDAQ: PTCT)

Community Rating: 1 Star: Ominous

27.98 -0.37 (-1.31%)

Quote as of

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $28.61
Previous Close $28.35
Daily Range $27.55 - $29.10
52-Week Range $13.15 - $34.65
Market Cap $841.5M
P/E Ratio -5.47
Dividend (Yield) $0.00 (0.0%)
Volume 174,118
Average Daily Volume 293,377
Current FY EPS -$2.96

How do you think PTCT
will perform against the market?

Top PTCT Bull/Bear Pitches

 

awallejr (< 20)
Submitted July 11, 2013

Speculation and a lot of insider buying

0 Replies Reply Report this Post
 

noataluren (0)
Submitted May 28, 2014

As a former PTC employee, this recommendation for conditional approval is a joke. None of the data are strong. The improvement for the 40 mg/kg/day dose over placebo was significant (after eliminating … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

3 Reasons Not to Worry About Sarepta Therapeutics Inc.

Sarepta Therapeutics fell on its 144-week data, but the approvability -- based on trials run by PTC Therapeutics and Prosensa -- is likely to be based on 48-week data.

Down 17%: Is Sarepta a Bad News Buy?

Sarepta Therapeutics is down over 20% today on disappointing clinical trial news. Here's what you need to know.

Sector Update: Healthcare Shares Flat Pre-Market

Sector Update: Healthcare

Why Wall Street is Betting Heavily Against Sarepta Therapeutics

Despite the FDA recently providing a regulatory pathway for Sarepta's Duchenne muscular dystrophy drug, the stock is still one of the most heavily shorted in health care. Here's why.

Why PTC Therapeutics Inc. Shares Took Off

PTC shares soar after receiving positive comments from Credit Suisse. However, here's what shareholders should really be focused on.

What You Need to Know About PTC Therapeutics' Promising DMD Drug

PTC Therapeutics (PTCT) won support from a key EU advisory committee last month, potentially clearing the way for a drug launch next year.

Surprising MS Drug Approval: Time to Buy?

The EU has issued a preliminary approval for Translarn, the Duchenne muscular dystrophy drug developed by PTC Therapeutics.

Why Ballard Power Systems, PTC Therapeutics, and VIVUS Are Today's 3 Best Stocks

The S&P 500 hits an intraday record high before falling, while Ballard Power Systems, PTC Therapeutics, and VIVUS put smiles on their shareholders' faces.

Is Prosensa Holding About to Soar?

Clinical-stage biotechs developing treatments for Duchenne muscular dystrophy have recently won a handful of political battles that have helped their drugs move forward on the regulatory front. Could Prosena be the next company to benefit from this change in political sentiment?

See More PTCT News...

Sector

Industry

PTC Therapeutics, Inc. (PTCT) Description

PTC Therapeutics, Inc. Website: http://www.ptcbio.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks